Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
PolarityTE receives NIH grant for a point-of-care device to treat chronic wounds » 08:07
09/21/20
09/21
08:07
09/21/20
08:07
PTE

PolarityTE

$1.10 /

+0.08 (+7.84%)

PolarityTE announced it…

PolarityTE announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health, NIH, for an application titled, "Fluid Management System for Point of Care Device for Novel Regenerative Treatment for Chronic Wounds." The Phase I grant, which totals approximately $245,000, is funded over a six-month period and will support research to apply for a subsequent larger Phase II grant. "I'm proud of the hard work the PolarityTE team dedicated to pursuing this grant and we are pleased to see that work validated by an award from the NIH," said David Seaburg, Chief Executive Officer of PolarityTE. Mr. Seaburg continued, "We will continue to leverage our scientific team's talent and pursue opportunities we believe will add value to the SkinTE franchise." "We are incredibly excited to receive this grant and look forward to working with the NIH to generate research supporting the development of a point-of-care device," said Dr. Nik Sopko, MD, PhD, Chief Scientific Officer. "We believe the ability to use products like SkinTE in a point-of-care setting will help many more patients gain access to novel treatments that can address unmet needs and deliver meaningful improvements to the standard of care."

ShowHide Related Items >><<
PTE PolarityTE
$1.10 /

+0.08 (+7.84%)

PTE PolarityTE
$1.10 /

+0.08 (+7.84%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
PTE PolarityTE
$1.10 /

+0.08 (+7.84%)

  • 12
    Feb
PTE PolarityTE
$1.10 /

+0.08 (+7.84%)

Over a week ago
Earnings
PolarityTE expects Q3 revenue to meet or exceed high-end of $2.7M-$3.2M range » 08:22
09/14/20
09/14
08:22
09/14/20
08:22
PTE

PolarityTE

$1.02 /

-0.055 (-5.14%)

Consensus $2.85M.…

Consensus $2.85M. PolarityTE said in a release, "PolarityTE announced that third quarter 2020 revenues will likely meet or exceed top end of the previous guided range of $2.7M to $3.2M." David Seaburg, CEO, commented, "We continue to see strong execution and momentum in SkinTE sales. Further, we expect the expansion of our COVID-19 testing capabilities through a recently announced partnership to help drive continued revenue growth in our services business. The revenue momentum we are seeing in both SkinTE sales and COVID-19 testing should significantly help mitigate our cash burn."

ShowHide Related Items >><<
PTE PolarityTE
$1.02 /

-0.055 (-5.14%)

PTE PolarityTE
$1.02 /

-0.055 (-5.14%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
PTE PolarityTE
$1.02 /

-0.055 (-5.14%)

  • 12
    Feb
PTE PolarityTE
$1.02 /

-0.055 (-5.14%)

Hot Stocks
PolarityTE, Co-Diagnostics enter partnership to expand COVID-19 testing platform » 08:23
09/08/20
09/08
08:23
09/08/20
08:23
PTE

PolarityTE

$1.04 /

-0.035 (-3.27%)

, CODX

Co-Diagnostics

$8.22 /

-1.06 (-11.42%)

PolarityTE (PTE), a…

PolarityTE (PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced that its subsidiary, Arches Research, has entered into a strategic partnership with Co-Diagnostics (CODX) to expand COVID-19 testing operations. Under the agreement, Arches will provide COVID-19 testing for customers referred by Co-Diagnostics and, to support additional demand, Co-Diagnostics will provide to Arches testing equipment in exchange for Arches' commitment to use only Co-Diagnostics tests on the equipment. Arches has previously been performing COVID-19 testing for its customers using Co-Diagnostics' Logix Smart COVID-19 test kit.

ShowHide Related Items >><<
PTE PolarityTE
$1.04 /

-0.035 (-3.27%)

CODX Co-Diagnostics
$8.22 /

-1.06 (-11.42%)

PTE PolarityTE
$1.04 /

-0.035 (-3.27%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
CODX Co-Diagnostics
$8.22 /

-1.06 (-11.42%)

05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/18/20 H.C. Wainwright
Co-Diagnostics price target raised to $35 from $20 at H.C. Wainwright
03/09/20 H.C. Wainwright
Co-Diagnostics price target raised to $20 from $4 at H.C. Wainwright
PTE PolarityTE
$1.04 /

-0.035 (-3.27%)

CODX Co-Diagnostics
$8.22 /

-1.06 (-11.42%)

  • 12
    Feb
CODX Co-Diagnostics
$8.22 /

-1.06 (-11.42%)

CODX Co-Diagnostics
$8.22 /

-1.06 (-11.42%)

PTE PolarityTE
$1.04 /

-0.035 (-3.27%)

CODX Co-Diagnostics
$8.22 /

-1.06 (-11.42%)

Over a month ago
Earnings
PolarityTE reports Q2 EPS (33c), consensus (38c) » 07:44
08/06/20
08/06
07:44
08/06/20
07:44
PTE

PolarityTE

$1.61 /

-0.02 (-1.23%)

Reports Q2 revenue…

Reports Q2 revenue $2.27M, consensus $830k.

ShowHide Related Items >><<
PTE PolarityTE
$1.61 /

-0.02 (-1.23%)

PTE PolarityTE
$1.61 /

-0.02 (-1.23%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
PTE PolarityTE
$1.61 /

-0.02 (-1.23%)

  • 12
    Feb
PTE PolarityTE
$1.61 /

-0.02 (-1.23%)

Options
Largest borrow rate increases among liquid names » 08:45
07/28/20
07/28
08:45
07/28/20
08:45
DGLY

Digital Ally

$3.29 /

-0.01 (-0.30%)

, BLDP

Ballard Power

$15.42 /

-0.395 (-2.50%)

, MVIS

MicroVision

$2.06 /

+0.045 (+2.24%)

, AXDX

Accelerate Diagnostics

$15.06 /

-0.58 (-3.71%)

, NK

NantKwest

$13.49 /

+0.28 (+2.12%)

, AMC

AMC Entertainment

$3.85 /

-0.16 (-3.99%)

, AMTD

TD Ameritrade

$36.58 /

-1.225 (-3.24%)

, LABD

Daily S&P Biotech Bear 3x Shares

$3.09 /

-0.27 (-8.05%)

, EWW

iShares MSCI Mexico

$33.57 /

+0.78 (+2.38%)

, PTE

PolarityTE

$1.62 /

-0.15 (-8.47%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Digital Ally (DGLY) 60.56% +5.06, Ballard Power (BLDP) 15.49% +4.43, Microvision (MVIS) 37.00% +2.87, Accelerate Diagnostics (AXDX) 67.70% +1.41, NantKwest (NK) 15.16% +1.01, AMC Entertainment (AMC) 73.94% +0.66, TD Ameritrade (AMTD) 0.78% +0.53, Direxion S&P Biotech Bear 3X (LABD) 3.30% +0.45, EWW (EWW) 2.30% +0.41, and PolarityTE (PTE) 13.45% +0.30.

ShowHide Related Items >><<
PTE PolarityTE
$1.62 /

-0.15 (-8.47%)

NK NantKwest
$13.49 /

+0.28 (+2.12%)

MVIS MicroVision
$2.06 /

+0.045 (+2.24%)

LABD Daily S&P Biotech Bear 3x Shares
$3.09 /

-0.27 (-8.05%)

DGLY Digital Ally
$3.29 /

-0.01 (-0.30%)

BLDP Ballard Power
$15.42 /

-0.395 (-2.50%)

AXDX Accelerate Diagnostics
$15.06 /

-0.58 (-3.71%)

AMTD TD Ameritrade
$36.58 /

-1.225 (-3.24%)

AMC AMC Entertainment
$3.85 /

-0.16 (-3.99%)

DGLY Digital Ally
$3.29 /

-0.01 (-0.30%)

06/29/20 Aegis
Digital Ally initiated with a Buy at Aegis
BLDP Ballard Power
$15.42 /

-0.395 (-2.50%)

07/13/20 Roth Capital
Ballard Power price target raised to $25 from $20 at Roth Capital
07/06/20 National Bank
Ballard Power initiated with a Sector Perform at National Bank
06/29/20 Roth Capital
Ballard Power upgraded to Buy at Roth Capital
06/29/20 Roth Capital
Ballard Power upgraded to Buy from Neutral at Roth Capital
MVIS MicroVision
$2.06 /

+0.045 (+2.24%)

05/06/20 Craig-Hallum
MicroVision rise driven by Microsoft speculation, says Craig-Hallum
02/26/20 Craig-Hallum
MicroVision downgraded to Hold from Buy at Craig-Hallum
02/26/20 H.C. Wainwright
MicroVision downgraded to Neutral from Buy at H.C. Wainwright
02/26/20 Ladenburg
Ladenburg downgrades MicroVision to Neutral on lost contract
AXDX Accelerate Diagnostics
$15.06 /

-0.58 (-3.71%)

05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
09/27/19 JPMorgan
Accelerate Diagnostics downgraded to Underweight from Neutral at JPMorgan
NK NantKwest
$13.49 /

+0.28 (+2.12%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
AMC AMC Entertainment
$3.85 /

-0.16 (-3.99%)

07/13/20 MKM Partners
MKM Partners lowers price targets in Cinema sector
06/30/20 Imperial Capital
AMC Entertainment price target lowered to $4 from $6 at Imperial Capital
06/29/20 Credit Suisse
Cinemark downgraded to Neutral from Outperform at Credit Suisse
06/29/20 Credit Suisse
AMC Entertainment downgraded to Underperform from Neutral at Credit Suisse
AMTD TD Ameritrade
$36.58 /

-1.225 (-3.24%)

07/24/20 Morgan Stanley
Morgan Stanley says Schwab share price doesn't reflect TD Ameritrade benefits
07/09/20 Wolfe Research
TD Ameritrade upgraded to Peer Perform from Underperform at Wolfe Research
06/08/20 Wolfe Research
TD Ameritrade downgraded to Underperform from Outperform at Wolfe Research
05/21/20 BofA
Charles Schwab downgraded to Neutral from Buy at BofA
LABD Daily S&P Biotech Bear 3x Shares
$3.09 /

-0.27 (-8.05%)

EWW iShares MSCI Mexico
$33.57 /

+0.78 (+2.38%)

PTE PolarityTE
$1.62 /

-0.15 (-8.47%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
PTE PolarityTE
$1.62 /

-0.15 (-8.47%)

MVIS MicroVision
$2.06 /

+0.045 (+2.24%)

DGLY Digital Ally
$3.29 /

-0.01 (-0.30%)

BLDP Ballard Power
$15.42 /

-0.395 (-2.50%)

AXDX Accelerate Diagnostics
$15.06 /

-0.58 (-3.71%)

AMTD TD Ameritrade
$36.58 /

-1.225 (-3.24%)

AMC AMC Entertainment
$3.85 /

-0.16 (-3.99%)

  • 25
    Jun
  • 08
    Jun
  • 02
    Jun
  • 28
    Feb
  • 12
    Feb
MVIS MicroVision
$2.06 /

+0.045 (+2.24%)

DGLY Digital Ally
$3.29 /

-0.01 (-0.30%)

BLDP Ballard Power
$15.42 /

-0.395 (-2.50%)

AMTD TD Ameritrade
$36.58 /

-1.225 (-3.24%)

AMC AMC Entertainment
$3.85 /

-0.16 (-3.99%)

NK NantKwest
$13.49 /

+0.28 (+2.12%)

MVIS MicroVision
$2.06 /

+0.045 (+2.24%)

DGLY Digital Ally
$3.29 /

-0.01 (-0.30%)

AXDX Accelerate Diagnostics
$15.06 /

-0.58 (-3.71%)

AMTD TD Ameritrade
$36.58 /

-1.225 (-3.24%)

AMC AMC Entertainment
$3.85 /

-0.16 (-3.99%)

NK NantKwest
$13.49 /

+0.28 (+2.12%)

MVIS MicroVision
$2.06 /

+0.045 (+2.24%)

LABD Daily S&P Biotech Bear 3x Shares
$3.09 /

-0.27 (-8.05%)

EWW iShares MSCI Mexico
$33.57 /

+0.78 (+2.38%)

DGLY Digital Ally
$3.29 /

-0.01 (-0.30%)

BLDP Ballard Power
$15.42 /

-0.395 (-2.50%)

AXDX Accelerate Diagnostics
$15.06 /

-0.58 (-3.71%)

AMC AMC Entertainment
$3.85 /

-0.16 (-3.99%)

Conference/Events
PolarityTE to hold a pharmaceutical update conference call » 15:55
07/27/20
07/27
15:55
07/27/20
15:55
PTE

PolarityTE

$1.60 /

-0.175 (-9.89%)

Management, along with…

Management, along with Dr. Armstrong, discuss positive top-line data from the interim analysis of SkinTE Diabetic Foot Ulcer Trial on a conference call to be held on July 27 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
PTE PolarityTE
$1.60 /

-0.175 (-9.89%)

PTE PolarityTE
$1.60 /

-0.175 (-9.89%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
PTE PolarityTE
$1.60 /

-0.175 (-9.89%)

  • 12
    Feb
Conference/Events
PolarityTE to hold a pharmaceutical update conference call » 09:23
07/27/20
07/27
09:23
07/27/20
09:23
PTE

PolarityTE

$1.77 /

+0.16 (+9.94%)

Management, along with…

Management, along with Dr. Armstrong, discuss positive top-line data from the interim analysis of SkinTE Diabetic Foot Ulcer Trial on a conference call to be held on July 27 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
PTE PolarityTE
$1.77 /

+0.16 (+9.94%)

PTE PolarityTE
$1.77 /

+0.16 (+9.94%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
PTE PolarityTE
$1.77 /

+0.16 (+9.94%)

  • 12
    Feb
Hot Stocks
PolarityTE announces data from interim analysis of SkinTE plus SOC trial » 08:06
07/24/20
07/24
08:06
07/24/20
08:06
PTE

PolarityTE

$1.61 /

-0.155 (-8.78%)

PolarityTE announced…

PolarityTE announced results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE plus standard of car, or SOC, compared to SOC alone. A total of 50 patients were evaluated across 13 sites with 25 patients receiving SkinTE plus SOC and 25 patients receiving only SOC. Mean wound area was 4.3 cm2 for the SkinTE plus SOC arm and 3.3 cm2 for the SOC arm. Mean wound age was 25.3 weeks for the SkinTE plus SOC arm and 22.1 weeks for the SOC arm. All SkinTE patients received only one application of the product, except two patients who received a reapplication due to inadvertent removal of the original product. Overall, 72% of patients treated with SkinTE plus SOC achieved wound closure by 12 weeks vs 32% of patients treated with SOC alone. Percent area reduction, or PAR, was greater with SkinTE plus SOC compared to SOC alone and was statistically significant at all predetermined timepoints. No significant differences between treatment groups in pain scores, wound quality of life, or Semmes-Weinstein Score.

ShowHide Related Items >><<
PTE PolarityTE
$1.61 /

-0.155 (-8.78%)

PTE PolarityTE
$1.61 /

-0.155 (-8.78%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
PTE PolarityTE
$1.61 /

-0.155 (-8.78%)

  • 12
    Feb
Over a quarter ago
Hot Stocks
Abeona Therapeutics appoints George Migausky, Paul Mann to board of directors » 07:37
06/17/20
06/17
07:37
06/17/20
07:37
ABEO

Abeona Therapeutics

$3.13 /

+0.01 (+0.32%)

, PTE

PolarityTE

$1.44 /

+0.015 (+1.06%)

, OCUL

Ocular Therapeutix

$8.83 /

+0.57 (+6.90%)

Abeona Therapeutics…

Abeona Therapeutics (ABEO) announced Board of Director appointments that strengthen and expand the Company's leadership. George Migausky and Paul Mann were appointed as independent directors, effective June 17, 2020. In addition to their Board service, Mr. Migausky will serve as Chairman of the Company's Audit Committee and Mr. Mann will serve as a member of the Audit Committee. Most recently, Migausky served as interim CFO of Ocular Therapeutix (OCUL) and Mann served as CFO at PolarityTE (PTE).

ShowHide Related Items >><<
PTE PolarityTE
$1.44 /

+0.015 (+1.06%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

ABEO Abeona Therapeutics
$3.13 /

+0.01 (+0.32%)

ABEO Abeona Therapeutics
$3.13 /

+0.01 (+0.32%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
PTE PolarityTE
$1.44 /

+0.015 (+1.06%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
PTE PolarityTE
$1.44 /

+0.015 (+1.06%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

ABEO Abeona Therapeutics
$3.13 /

+0.01 (+0.32%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

Hot Stocks
PolarityTE announces publication of two SkinTE manuscripts » 08:23
06/01/20
06/01
08:23
06/01/20
08:23
PTE

PolarityTE

$0.97 /

-0.0423 (-4.17%)

PolarityTE reported the…

PolarityTE reported the recent publication of two peer-reviewed manuscripts involving the application of SkinTE in a pilot study of diabetic foot ulcers and a 15-patient case series evaluating multiple wound types. A publication reporting results from the company's diabetic foot ulcer, or DFU, pilot study was published in the International Wound Journal. The primary endpoint of the pilot was the rate of closure at 12 weeks following SkinTE treatment. According to the abstract, "All 11 DFUs demonstrated successful graft take. Ten DFUs closed within 8 weeks. The median time-to-complete closure was 25 days." PolarityTE is currently conducting a multi-center randomized controlled trial to further evaluate the use of SkinTE in DFUs. Another publication was published in Plastic and Reconstructive Surgery - Global Open. The retrospective, noncontrolled, 15-patient case series evaluated various wound etiologies, including five acute and chronic, four acute traumatic, and six chronic wounds. According to the publication, "All wounds were closed with a single application of AHSC manufactured from a single tissue harvest."

ShowHide Related Items >><<
PTE PolarityTE
$0.97 /

-0.0423 (-4.17%)

PTE PolarityTE
$0.97 /

-0.0423 (-4.17%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
PTE PolarityTE
$0.97 /

-0.0423 (-4.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.